A5058125456- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Immune cells in cancer
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- Nanoplatforms for cancer theranostics
- Chemokine receptors and signaling
- Viral-associated cancers and disorders
- Melanoma and MAPK Pathways
- Immune Response and Inflammation
- Glycosylation and Glycoproteins Research
- Reproductive System and Pregnancy
- Colorectal Cancer Treatments and Studies
- Cutaneous Melanoma Detection and Management
- vaccines and immunoinformatics approaches
- Macrophage Migration Inhibitory Factor
- Lymphoma Diagnosis and Treatment
- Parvovirus B19 Infection Studies
- Neuroinflammation and Neurodegeneration Mechanisms
- Cancer Research and Treatments
- Inflammatory mediators and NSAID effects
- Chronic Lymphocytic Leukemia Research
- Cytomegalovirus and herpesvirus research
Karolinska Institutet
2014-2023
Karolinska University Hospital
2013-2023
Svenska Örtmedicinska Institute
2016
German Cancer Research Center
2013
Heidelberg University
2013
UPMC Hillman Cancer Center
2011
Bristol-Myers Squibb (United States)
2011
Icahn School of Medicine at Mount Sinai
2011
Yale University
2011
Università di Camerino
2010
Thirty-nine tumor-bearing patients with metastatic melanoma were treated 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of 25 who received complete treatment, 7 displayed tumor regressions. All but one these regressions involved cutaneous metastases. Three and 2 led to a disease-free state, which persisted for more than years after beginning treatment. evidence cytolytic T lymphocyte (CTL) response found in blood 4 analyzed,...
Myeloid-derived suppressor cells (MDSC) have emerged as key immune modulators in various tumor models and human malignancies, but their characteristics humans remain to be unequivocally defined. In this study, we examined circulating CD14(+)HLA-DR(-/low) MDSC 34 advanced malignant melanoma (MM) patients. Their frequency is significantly increased associated with disease activity. Contrary the common notion that are a heterogeneous population of exclusively immature cells, find coexpression...
The sixth “Melanoma Bridge Meeting” took place in Naples, Italy, December 1st–4th, 2015. four sessions at this meeting were focused on: (1) molecular and immune advances; (2) combination therapies; (3) news immunotherapy; 4) tumor microenvironment biomarkers. Recent advances biology immunology has led to the development of new targeted immunotherapeutic agents that prolong progression-free survival (PFS) overall (OS) cancer patients. Immunotherapies particular have emerged as highly...
The purpose of this study was to evaluate the prognostic value Immunoscore in patients with stage III colon cancer (CC) and analyze its association effect chemotherapy on time recurrence (TTR).
Abstract Although alterations in CD3‐associated signal‐transducing molecules tumor‐infiltrating T cells of patients with advanced cancer have been previously described, the mechanism behind these changes is not known. We demonstrate that macrophages isolated from metastatic lymph nodes malignant melanoma down‐regulate levels CD3ζ autologous peripheral blood cells. Lipopolysaccharide (LPS)‐ or phorbol 12‐myristate 13‐acetate (PMA)‐stimulated monocytes derived healthy donors also induced...
Interleukin 10 (IL-10) is a cytokine with variety of reported effects including inhibition monocyte major histocompatibility complex (MHC) class II-dependent antigen presentation, type 1 helper T cell production, and proliferation. Herein we report the effect IL-10 pretreatment on presentation to tumor- allo-specific CD8+ cytotoxic lymphocytes (CTL). Prior incubation human melanoma cells recombinant (rIL-10) for 48-72 h resulted in dose-dependent, up 100% inhibition, autologous CTL-mediated,...
Prostate-specific antigen (PSA) is a serine protease secreted at low levels by normal luminal epithelial cells of the prostate and in significantly higher cancer cells. Therefore, PSA potential target for various immunotherapeutical approaches against cancer. DNA vaccination has been investigated as immunotherapy infectious diseases patients specific treatment certain animal models. In studies, we have demonstrated that with plasmid vector pVAX/PSA results PSA-specific cellular response...
Tumors can suppress the host immune system by employing a variety of cellular modulators, such as regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells (MDSC). In peripheral blood patients with advanced stage melanoma, there is an accumulation CD14(+)HLA-DR(lo/-) MDSC that autologous ex vivo in STAT-3-dependent manner. However, precise mechanistic basis underlying this effect unclear, particularly regard to whether induction mechanism relies on cell-cell...
The fifth "Melanoma Bridge Meeting" took place in Naples, December 1–5th, 2015. main topics discussed at this meeting were: Molecular and Immuno advances, Immunotherapies Combination Therapies, Tumor Microenvironment Biomarkers Immunoscore. natural history of cancer involves interactions between the tumor immune system host. infiltration site may be indicative host response. Significant correlations were shown levels cell tumors patient's clinical outcome. Moreover, incredible progress comes...
Abstract Blocking the immune checkpoint molecule CTL antigen-4 (CTLA-4) with ipilimumab has proven to induce long-lasting clinical responses in patients metastatic melanoma. To study early response that takes place after CTLA-4 blockade, peripheral blood monitoring was conducted five undergoing treatment at baseline, three and nine weeks administration of first dose. Along T-cell population analysis, this work primarily focused on an in-depth myeloid-derived suppressor cell (MDSC)...
// Yago Pico de Coaña 1 , Maria Wolodarski 1, 2 Isabel Poschke 3 Yuya Yoshimoto 4 Yuan Yang 5 Nyström Ulrika Edbäck Suzanne Eghyazi Brage Andreas Lundqvist 6 Giuseppe V. Masucci Johan Hansson Rolf Kiessling Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden University Hospital Solna, Division Molecular Gastrointestinal Tumors, German Research Center, Heidelberg, Germany Radiation Oncology, Gunma Graduate School Medicine, Maebashi, Gunma,...
Abstract Impaired immune responses in cancer patients have been associated with oxidative stress. Increased levels of reactive oxygen species released from activated, tumor-infiltrating macrophages or granulocytes may therefore constitute a hurdle for effective immunotherapy against cancer. In this study, we investigated functional consequences and molecular events T cells exposed to low We observed that cytokine production human PBMC, upon stimulation an HLA-A*0201-restricted influenza...
Report results of patient-reported health-related quality life (HRQoL) and symptoms from phase III KEYNOTE-006 study pembrolizumab versus ipilimumab in patients with ipilimumab-naive advanced melanoma.Patients received 10 mg/kg every 2 (Q2W) or 3 weeks (Q3W) for up to years, four cycles Q3W. The European Organisation Research Treatment Cancer Quality Life Questionnaire C30 (EORTC QLQ-C30) was administered at baseline throughout the study. Patient-reported outcome (PRO) analyses were...